MGX
Metagenomi Therapeutics, Inc.
Latest Form 4:Sale$4KbyWapnick Pamela (Chief Financial Officer) · filed Jun 10, 2026
Metagenomi Therapeutics, Inc. (MGX) has 13 SEC Form 4 filings (14 transaction rows) in the rolling window, disclosed by 4 distinct insiders. Most recent filing: Jun 10, 2026.
The most active filer is Chief Financial Officer Wapnick Pamela with 3 filings.
- Industry:Biotechnology
- CEO:Jian Irish
- Employees:202
- HQ:Emeryville, US
- IPO:2006-04-06
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$28K
reported sales (SEC code S)
Unique Insiders
4
in the rolling window
Market Cap
$46.3M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
Wapnick PamelaFirst in 3 months | Chief Financial Officer | Sale | 2,884 | $4K | Jun 10 | SEC ↗ |
Irish JianFirst in 3 months | See Remarks | Sale | 3,737 | $5K | Jun 10 | SEC ↗ |
Wein MatthewFirst in 3 months | See Remarks | Sale | 558 | $725 | Jun 10 | SEC ↗ |
Irish JianFirst in 3 months | Chief Executive Officer | Sale | 1,607 | $3K | Mar 9 | SEC ↗ |
Wapnick PamelaFirst in 3 months | Chief Financial Officer | Sale | 1,581 | $3K | Mar 9 | SEC ↗ |
Wein MatthewFirst in 3 months | See Remarks | Sale | 482 | $771 | Mar 9 | SEC ↗ |
Wapnick PamelaFirst filing | Chief Financial Officer | Sale | 1,576 | $3K | Dec 8 | SEC ↗ |
Irish JianFirst filing | Chief Executive Officer | Sale | 1,602 | $3K | Dec 8 | SEC ↗ |
Thomas Brian C.First filing | Director | Sale | 3,830 | $7K | Dec 8 | SEC ↗ |
Wein MatthewFirst filing | See Remarks | Sale | 199 | $353 | Dec 8 | SEC ↗ |
Related companies
Metagenomi Therapeutics, Inc. is in the Healthcare sector.